Potential inhibitor for 2019-novel coronaviruses in drug development

Xiaohui Xu, Zi-long Dang, Lei Zhang, L. Zhuang, Wutang Jing, L. Ji, Guoyu Qiu
{"title":"Potential inhibitor for 2019-novel coronaviruses in drug development","authors":"Xiaohui Xu, Zi-long Dang, Lei Zhang, L. Zhuang, Wutang Jing, L. Ji, Guoyu Qiu","doi":"10.4103/ctm.ctm_3_20","DOIUrl":null,"url":null,"abstract":"The coronavirus disease 2019 (COVID-19), which is first detected in Wuhan, China, is a virus identified as the cause of pneumonia. In the event of epidemic outbreak, a series of actions have been taken by the Chinese government to control the pandemic of the virus, and effective medical methods are in urgent need to prevent COVID-19 infection and cure the disease, especially a drug that can suppress COVID-19 is urgently needed. However, there are no specific drugs and vaccine that can prevent coronavirus infection. Some research works on the transmissibility, severity, and other features associated with this virus are ongoing. Some works about new drug against COVID-19 are carried out; more time is required to develop an effective drug against pneumonia caused by COVID-19. Now, to develop broad-spectrum antiviral agents, there is a quick method to identify drugs with high binding capacity with COVID-19 by virtual screening based on the clinical drug libraries; all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of COVID-19. In this article, we summarize the discovery and clinical application of specific drugs against COVID-19 as potential inhibitors to alleviate the current epidemic.","PeriodicalId":9428,"journal":{"name":"Cancer Translational Medicine","volume":"17 1","pages":"17 - 20"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Translational Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ctm.ctm_3_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

The coronavirus disease 2019 (COVID-19), which is first detected in Wuhan, China, is a virus identified as the cause of pneumonia. In the event of epidemic outbreak, a series of actions have been taken by the Chinese government to control the pandemic of the virus, and effective medical methods are in urgent need to prevent COVID-19 infection and cure the disease, especially a drug that can suppress COVID-19 is urgently needed. However, there are no specific drugs and vaccine that can prevent coronavirus infection. Some research works on the transmissibility, severity, and other features associated with this virus are ongoing. Some works about new drug against COVID-19 are carried out; more time is required to develop an effective drug against pneumonia caused by COVID-19. Now, to develop broad-spectrum antiviral agents, there is a quick method to identify drugs with high binding capacity with COVID-19 by virtual screening based on the clinical drug libraries; all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of COVID-19. In this article, we summarize the discovery and clinical application of specific drugs against COVID-19 as potential inhibitors to alleviate the current epidemic.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2019新型冠状病毒药物开发中的潜在抑制剂
在中国武汉首次发现的新型冠状病毒病(COVID-19)是一种被确定为肺炎病因的病毒。在疫情爆发的情况下,中国政府已经采取了一系列措施来控制病毒的大流行,迫切需要有效的医学方法来预防COVID-19感染和治愈疾病,特别是迫切需要一种可以抑制COVID-19的药物。然而,目前还没有特定的药物和疫苗可以预防冠状病毒感染。有关该病毒的传播性、严重性和其他相关特征的一些研究工作正在进行中。开展了一些抗COVID-19新药研制工作;需要更多的时间来开发对抗COVID-19引起的肺炎的有效药物。目前,为了开发广谱抗病毒药物,有一种基于临床药物库的虚拟筛选方法,可以快速识别出与COVID-19具有高结合能力的药物;这些药物已广泛应用于临床,安全性有保障,可能成为治疗COVID-19感染的有希望的候选药物。本文就新型冠状病毒肺炎特异性药物的发现和临床应用进行综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Cyclooxygenase-2 contributes to mutant epidermal growth factor receptor lung tumorigenesis by promoting an immunosuppressive environment Comparison of histopathological grading and staging of breast cancer with p53-positive and transforming growth factor-beta receptor 2-negative immunohistochemical marker expression cases Characteristics and outcome of patients with pheochromocytoma Chemical compositions and antiproliferative effect of essential oil of asafoetida on MCF7 human breast cancer cell line and female wistar rats Protein disulfide isomerase A3: A potential regulatory factor of colon epithelial cells
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1